Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$29.72 USD

29.72
302,325

-0.22 (-0.73%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $29.78 +0.06 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 248)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

AMN Healthcare's (AMN) New Buyout to Aid Healthcare Staffing

by Zacks Equity Research

AMN Healthcare's (AMN) acquisition of Connetics USA is expected to significantly boost its Nurse and Allied Solutions segment globally.

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat

by Zacks Equity Research

Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.

OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.

Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays

by Zacks Equity Research

Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.

Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues

by Zacks Equity Research

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.

Allscripts' (MDRX) Stock Falls 8.8% Post Q1 Earnings Miss

by Zacks Equity Research

Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.

    Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat

    by Zacks Equity Research

    Glaukos' (GKOS) soft Q1 results fail to impress investors.

    Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

    by Zacks Equity Research

    Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.

      DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results

      by Zacks Equity Research

      DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.

      Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat

      by Zacks Equity Research

      Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.

      AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates

      by Zacks Equity Research

      AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.

      McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates

      by Zacks Equity Research

      McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.

      Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

      by Zacks Equity Research

      Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

      Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates

      by Zacks Equity Research

      Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.

      DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View

      by Zacks Equity Research

      Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.

      CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?

      by Zacks Equity Research

      CPSI vs. OMCL: Which Stock Is the Better Value Option?

      Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, Up Y/Y

      by Zacks Equity Research

      Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.

      CONMED's (CNMD) Q1 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      CONMED's (CNMD) first-quarter earnings reflect strong segmental performance.

      PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat

      by Zacks Equity Research

      PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.

      LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss

      by Zacks Equity Research

      LHC Group's (LHCG) first-quarter results benefit from organic growth in both home health as well as hospice admissions.

      Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top

      by Zacks Equity Research

      Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.

      BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View

      by Zacks Equity Research

      The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.